AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

The Phase II trial saw Recce 327 achieving all primary and secondary endpoints as the company looks to launch a Phase III trial.

If you are looking for a natural alternative for pain relief and muscle soreness, CBD might be able to help. With its ...

Recce Pharmaceuticals Ltd has received positive findings from a Phase II clinical trial evaluating RECCE® 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), ...

Recce Pharmaceuticals up ~9% after successful phase II clinical trial assessing efficacy and safety of R327G in patients with ...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute ...

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $25.00 price ...

The recalled products were sold across 32 states — including Massachusetts, Connecticut, Rhode Island and Vermont.

DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) will likely be posting its quarterly earnings results before the ...